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Abstract
Primary rodent astroglial-enriched cultures are the most popular model to study astroglial biology
in vitro. From the original methods described in the 1970's a great number of minor modifications
have been incorporated into these protocols by different laboratories. These protocols result in
cultures in which the astrocyte is the predominant cell type, but astrocytes are never 100% of cells
in these preparations. The aim of this review is to bring attention to the presence of microglia in
astroglial cultures because, in my opinion, the proportion of and the role that microglial cells play
in astroglial cultures are often underestimated. The main problem with ignoring microglia in these
cultures is that relatively minor amounts of microglia can be responsible for effects observed on
cultures in which the astrocyte is the most abundant cell type. If the relative contributions of
astrocytes and microglia are not properly assessed an observed effect can be erroneously
attributed to the astrocytes. In order to illustrate this point the case of NO production in activated
astroglial-enriched cultures is examined. Lipopolysaccharide (LPS) induces nitric oxide (NO)
production in astroglial-enriched cultures and this effect is very often attributed to astrocytes.
However, a careful review of the published data suggests that LPS-induced NO production in
rodent astroglial-enriched cultures is likely to be mainly microglial in origin. This review considers
cell culture protocol factors that can affect the proportion of microglial cells in astroglial cultures,
strategies to minimize the proportion of microglia in these cultures, and specific markers that allow
the determination of such microglial proportions.
Review
Our knowledge of the functional potentialities of astro-
cytes has not ceased to grow in the last decades. Astrocytes
are now recognized as important players in fundamental
CNS functions such as energy metabolism [1], neuro-
transmission [2], maintenance of the blood-brain barrier
[3], extracellular ion homeostasis [4] or cerebrovascular
regulation [5] and they also play key roles in neuroinflam-
mation [6] or repair [7]. Much of this knowledge has been
obtained through in vitro studies. Although astroglial cell
lines exist, such as rat C6 or human U373, primary cul-
tures are by far the most commonly used model to study
astroglial biology in vitro. A note regarding terminology:
Primary cultures are, strictly speaking, those prepared by
plating cells directly after isolation from tissue. When a
primary culture is subcultured we obtain secondary cul-
tures, tertiary cultures, etc. In this review the term "pri-
mary culture" is used in a less strict way to include also
subcultures, except in Additional File 1 in which "pri-
mary" means without subculture.
Primary astroglial-enriched cultures are easy to prepare,
reproducible and versatile and can be obtained from vir-
tually any CNS region. Most laboratories prepare astro-
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primary astroglial-enriched cultures are also common
whereas other species are used more seldom. Astroglial-
enriched primary cultures can be prepared from organ-
isms of any age, including embryonic, foetal, neonatal,
young, adult and old organisms. In terms of yield and
purity, the optimal age is while astrogenesis peaks; this
occurs after the peak of neurogenesis and before the peak
of oligodendrogenesis. In mice and rats this optimal win-
dow spans a period from 2–3 days prenatal to 2–3 days
postnatal for cortex and most CNS regions [8], but not for
cerebellum where it spans between post-natal days 4 and
7 [9].
Most protocols for preparing astroglial-enriched cultures
from rat/mouse late embryos/neonates are derived from
the seminal work of Booher and Sensenbrenner [10] or
the later modification by McCarthy and de Vellis [11]. A
completely different approach, not discussed here, is the
culture of acutely isolated astrocytes [12,13]. Astrocytes
are able to grow in a great variety of in vitro conditions,
however, and virtually every laboratory has created its
own more or less modified protocol (see e.g. Additional
File 1). In most of these protocols the dissected tissue is
dissociated by mechanical and/or enzymatic digestion
and the dissociated cells are plated. If adequate plating
density, plate coating, medium composition and regime
of medium changes are used, astrocytes proliferate rapidly
and a confluent culture is obtained generally 7–14 days
after plating. In these cultures type-I astrocytes form a
monolayer with variable amounts of type II astrocytes.
Since astrocytes constitute the most abundant cell type in
these preparations, they are often described as astroglial,
astroglial-rich, astroglial-enriched or even pure astroglial
cultures. However, in none of these preparations do astro-
cytes represent 100% of cells. Depending on culture con-
ditions, oligodendrocytes [11,14], neurons [15], various
types of precursors [16,17], ependymal cells [14,17],
fibroblasts [18-20], endothelial cells [20,17,21] or micro-
glial cells [17,22] can be present in these cultures, gener-
ally in small proportions.
The purpose of this review is to bring attention to the pres-
ence of microglia in astroglial cultures. In my opinion
both the proportion and the role that microglial cells play
in astroglial cultures are often underestimated. One possi-
ble explanation for such underestimation is historical.
When the first protocols for astroglial cultures were estab-
lished no good markers for microglial cells in vitro
existed. As a result, the questions of whether microglial
cells were present in astroglial cultures and in what pro-
portion were not addressed in classical papers in the field
[10,11,14]. These publications were used as a guide by
many groups and this may partly explain why the pres-
ence of microglial cells remained unquestioned when
good markers for microglial cells in vitro later became
available. Another reason why microglial cells in astro-
glial cultures have sometimes been ignored is related to
the image obtained after glial fibrillary acidic protein
(GFAP) immunostaining, by far the most common
approach to estimate the proportion of astrocytes in these
cultures. Since astrocytes form a confluent monolayer,
GFAP immunostaining results in an image in which virtu-
ally the entire cultured area is covered by astrocytes, giving
the false impression that there is not much room for other
cells (Fig 1). Authors may conclude that since there are no
GFAP-free spaces, the proportion of non astroglial cells
must be minimal and no further studies to establish the
proportions of non astroglial cell types are deemed neces-
sary. However, the reality is that non-astroglial cells can be
present above and below the astroglial monolayer, and
that specific markers should be used to estimate the pro-
portions of these contaminating cell populations.
Relevance of microglial cells in astroglial cultures
Why is it important to know the proportion of microglia
in astroglial cultures and to keep this proportion as low as
possible? First, because astrocytes and microglia are very
different types of cells. One should not dismiss the pres-
ence of microglial cells in astroglial cultures with the
thought that "after all, they are both glial cells". Their
ontogenic origins are different – neuroectodermal for
astrocytes, monocytic for microglia – their physiological
roles are different, and many of their responses upon acti-
vation are also different. Microglia can do things that
astrocytes cannot and small amounts of microglia can
sometimes be responsible for the effects observed in cul-
tures in which the astrocyte is the predominant cell type.
If the relative contributions of astrocytes and microglia are
not properly assessed one can erroneously attribute a
microglia-derived effect to astrocytes, just because they are
the predominant cell type. I will illustrate this point with
the example of the production of NO in activated astro-
glial-enriched cultures.
NO production by astrocytes and microglia in vitro
A great amount of literature exists regarding NO produc-
tion by astroglial-enriched cultures, particularly upon LPS
activation of cultures. Most reports analyze NO produc-
tion by measuring the accumulation of released NO in the
culture medium and many assume that such NO produc-
tion is astroglial. However, a review of the literature sug-
gests that this assumption is not correct in many of these
studies. NO can be produced by NO synthases 1, 2 and 3
(NOS1, NOS2, and NOS3, also known as cNOS, iNOS
and eNOS, respectively) and these enzymes can be
expressed by astrocytes [23]. The NOS2 inhibitor 1400W
abolishes the LPS-induced NO production in rodent glial
cultures [24] suggesting that in these experimental condi-
tions NO production by NOS1 or NOS3 isoforms is neg-Page 2 of 11
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type producing NO in LPS-activated primary glial cultures
is to identify the NOS2 expressing cells. Table 1 summa-
rizes all the studies that, to my knowledge, have addressed
the question of what cell types express NOS2 in LPS-acti-
vated rodent astroglial-enriched or mixed glial cultures. It
is clear from these data that in these cell preparations LPS
induces NOS2 expression in microglia since co-localiza-
tion of NOS2 with a microglial marker was observed in
every study (n = 10) in which this was analyzed. The evi-
dence that LPS also induces NOS2 expression in cultured
rodent astrocytes is certainly weaker. In most studies (10
out of 16) the authors failed to observe any NOS2 positive
astrocyte by NOS2-GFAP double labelling. Among the
studies that have reported the presence of NOS2 positive
astrocytes in LPS-treated rodent cultures, possibly the
most convincing images are found in the recent reports of
Hamby et al [25,26]. Interestingly, this group found that
the number of NOS2-positive astrocytes is extremely low
after LPS activation, and that this increases after activation
with LPS + interferon-γ (IFNγ) and especially after activa-
tion with LPS + IFNγ + transforming growth factor β1
(TGFβ1) [25]. This indicates that the expression of NOS2
in activated astrocytes and microglia is dependent on the
activation stimulus. Von Bernhardi et al [27] did show
NOS2-positive astrocytes, but NOS2 expression was
stronger in microglia. NOS2-positive astrocytes were also
observed in the only study from this series performed on
spinal cord astroglial cultures [28] suggesting a possible
regional heterogeneity on the ability of activated astro-
cytes to express NOS2. Finally, some reports identified
NOS2-positive cells as astrocytes by GFAP staining despite
the fact that these cells had the morphology of microglia
in vitro [29,30]. In my experience treatment of murine pri-
mary mixed glial cultures with LPS (1 µg/ml) and IFNγ
(0.5 ng/ml) for 24 hours results in intracellular NOS2
immunoreactivity in numerous cells. Double labelling of
NOS2 with GFAP or CD11b reveals that the great majority
of NOS2 immunoreactive cells are microglia, as identified
by CD11b immunoreactivity (Fig 2). Less than 2% of all
NOS2 positive cells were CD11b-negative and less than
1% of all NOS2 positive cells were positive for GFAP.
Rodent astrocytes are certainly able to express NOS2 in
vitro [31,32] and in vivo [23] and the production of NO
by human astrocytes is also a confirmed observation
[33,34]. Nevertheless, these results show that upon LPS or
LPS + IFNγ activation of rodent astroglial-enriched/mixed
glial cultures NOS2 is strongly expressed in microglial
cells whereas the expression of NOS2 in astrocytes is
weaker than in microglia if not completely absent. In
agreement with this, the NO production induced by LPS
in highly-enriched astroglial cultures, virtually devoid of
microglia, is barely measurable by the Griess reaction
whereas the same method reveals a robust NO production
A) Phase contrast image of a confluent murine primary corti-cal mixed glial cultureFigure 1
A) Phase contrast image of a confluent murine primary corti-
cal mixed glial culture. A monolayer of type-I astrocytes is 
observed with some refringent microglia-looking cells. This 
image could suggest that this is an almost pure astroglial cul-
ture. B) GFAP immunostaining of the same field in A seems 
to confirm this impression. It is difficult to count how many 
astrocytes are in the field but since the whole field is covered 
by astrocytes one might conclude that indeed this is an 
almost pure astroglial culture. C) Immunostaining with the 
microglial marker CD11b reveals the presence of numerous 
(20) microglial cells in the field. These are mainly not the 
round refringent microglial cells typically recovered by shak-
ing and found on top of the astrocytes. Instead these are 
more ramified cells, in direct contact with the bottom of the 
well, between the astrocytes or below them. D) Hoechst 
staining allows the easy quantification of the total number of 
cells in a culture. In this field there are 109 cells and micro-
glial cells represent 18%. Hoechst 33258 staining also reveals 
the different nuclear morphology of astrocytes and microglia. 
Bar, 100 µmPage 3 of 11







































































Table 1: Astroglial and microglial NOS2 immunoreactivity in LPS-activated mouse/rat astroglial-enriched/mixed glial cultures. This table summarizes all the studies that, to my 
knowledge, have addressed the question of what cell types express NOS2 in LPS-activated rodent astroglial-enriched or mixed glial cultures. Studies using activating stimuli other than 
LPS or studies on human glial cultures are not included in this table. Reports describing the presence of NADPH diaphorase in LPS-treated astroglial-enriched cultures (e.g [77]) are also 
not included because NOS2 is only one of many brain enzymes that exhibit NADPH diaphorase activity [78].






[29] Fig 4 Mouse-Neonatal-Whole Brain 1 - - Yes (?) Yes (Mac1) "The number of GFAP/NOS2 
positive cells was low". NOS2(+) 
cells have microglial morphology 
and not a clear GFAP staining
DAB-Ni and DAB
[68] Fig 2 Rat-Neonatal-Cortex 100 - 24 h No - NOS2(+) cells have a microglial 
appearance but no double 
labelling is done
IF
[69] Fig 1 Rat-Neonatal-Cortex 1 - 24 h No Yes (Isolectin-B4) IF
[70] Fig 1 Rat-Neonatal-Forebrain 1 - 12 h, 24 h, 48 h No - NOS2(+) cells have a microglial 
appearance but no double 
labelling NOS2/microglia is done
DAB and AP
[71] Fig 3 Rat-Neonatal-Cortex 2 IFNγ (100 U/ml) 18 h No Yes (OX-42) IF
[72] Fig 2 Rat-Neonatal-Cortex 2 IFNγ (100 U/ml) 18 h No Yes (OX-42) IF
[73] Fig 3 Rat-Neonatal-Cortex 2 IFNγ (100 U/ml) 18 h - Yes (OX-42) "All NOS2(+) cells were OX-
42(+)"
IF
[74] Fig 2 Rat-Neonatal-Cortex 2 IFNγ (100 U/ml) 18 h No - IF
[39] Figs 2,3,5 Rat-Neonatal-Cortex 10 - 48 h No Yes (OX-42) IF
[30] Fig 3 Rat-Neonatal-Neopallium 0,025 IFNγ (100 U/ml) 24 h Yes (?) - Some double GFAP-NOS2(+) 
cells do not look like astrocytes
IF
[75] Fig 5 Rat-Neonatal-Cortex 1 IFNg (100 U/ml) 48 h No Yes (Isolectin-B4) IF
[28] Fig 1 Rat-Neonatal-Spinal cord 1 - 24 h Yes - Double GFAP-NOS2(+) cells. 
Double NOS2-microglial staining 
not done because "these 
cultures had no OX42 positive 
cells"
IF
[76] Fig 3 Rat-Neonatal-Cortex 0,1 - 24 h No Yes (OX-42) "All NOS2(+) cells were OX-
42(+)"
IF
[27] Fig 2 Rat-Neonatal-Cortex 1 IFNγ (10 ng/ml) 14 h Yes Yes (Isolectin-B4) "NOS2 staining is much stronger 
in microglia than in astrocytes"
IF
[24] Fig 6 Mouse-Neonatal-Cortex 1 CGS21680 (100 
nM)
48 h No Yes (Tomato lectin) IF
[26] Fig 6 Mouse-Neonatal-Cortex 2 IFNγ (3 ng/ml) 24 h Yes - Double GFAP-NOS2(+) cells IF
[25] Fig 8 Mouse-Neonatal-Cortex 2 IFNγ (3 ng/ml) 
and TGFβ1 (3 
ng/ml)
14 h Yes - Double GFAP-NOS2(+) cells. 
The number of NOS2(+) 
astrocytes is very low after LPS 
but high after TGFβ1 + LPS + 
IFNγ treatment
IF
* GFAP was the astroglial marker used in all the studies
** DAB: diaminobenzidine, DAB-Ni: DAB-Nickel; AP: Alkaline phosphatase; IF: immunofluorescence
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Murine primary cortical mixed glial culture were treated with LPS (1 µg/ml) and IFNγ (0.5 ng/ml) for 24 hours and immunos-tained fo  NOS2 (A, B), GFAP (C) or CD11b (D)Figur  2
Murine primary cortical mixed glial culture were treated with LPS (1 µg/ml) and IFNγ (0.5 ng/ml) for 24 hours and immunos-
tained for NOS2 (A, B), GFAP (C) or CD11b (D). A and C show the same field and E is their merged image. B and D show the 
same field and F is their merged image. In control cultures NOS2-immunoreactive cells were not observed (data not shown). 
There is (LPS + IFNγ)-induced NOS2 expression in numerous cells (A, B). NOS2-positive cells were almost never GFAP immu-
noreactive (A, C, E) indicating a lack of NOS2 expression in most astrocytes. In contrast, virtually all NOS2-positive cells 
(>98%) were identified as microglia by their CD11b immunoreactivity. Nuclei are counterstained with Hoechst 33258 in A-D. 
NOS2-positive cells were identified with a rabbit anti-NOS2 antibody (1:500, BD Biosciences), GFAP-positive cells with a 
mouse anti-GFAP antibody (1:1000, Sigma) and CD11b-positive cells with 5C6 mouse anti-CD11b antibody (1:400, Serotec). 
Bar, 100 µm.
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41]. These data suggest that LPS-induced NO production
in rodent primary cortical astroglial cultures is mainly
produced by "contaminating" microglial cells and not by
astrocytes as often assumed.
There are similar concerns regarding studies identifying
the cell of origin for apolipoprotein-E (apoE) production.
In the CNS apoE appears to be produced in vivo by glial
cells, mainly by astrocytes. Rodent cortical primary mixed
glial cultures produce and release apoE [40,42-45].
Because of the in vivo data and because astrocytes are the
main cell type in these cultures one might infer that apoE
production in these cell preparations is basically astroglial
in origin. However, highly-enriched astroglial cultures do
not produce or release apoE whereas highly-enriched
microglial cultures do [40], and apoE immunoreactivity
in rodent mixed glial cultures co-localizes with microglial
and not with astroglial markers [46]. Therefore apoE is
another example showing that microglial cells, despite
not being the most abundant cell type, can be responsible
for observations made in astroglial-enriched/mixed glial
cultures.
A great number of studies are published every year using
astroglial-enriched cultures to describe the expression of
all sorts of molecules, e.g. cytokines, chemokines, adhe-
sion molecules. Most of these studies identify such expres-
sion by methods that lack cellular resolution (PCR,
Western blot, ELISA, etc.) and many assume that the astro-
cyte is the cell type causing the observed effects. The exam-
ples of NOS2 and apoE show that this assumption may
sometimes be incorrect, and indicate how important the
estimation of the microglial proportion is when working
with astroglial-enriched/mixed glial cultures.
Microglial cells in astroglial cultures: how to estimate and 
affect their proportion
Determination of the proportion of microglia in astroglial
cultures is seldom done (see e.g. Additional File 1), but in
fact such determination is easy. Staining of microglia in
fixed cultures with specific markers, antibodies or lectins,
gives reliable results and, once stained, microglial cells are
easy to count. In my experience, the antibodies ED1,
which recognizes the lysosomal glycoprotein CD68, and
OX-42, which recognizes CD11b, are good microglial
markers in rat astroglial cultures [47,48], whereas the 5C6
anti CD11b antibody (see Fig 1) and the lectin from Lyc-
opersicon sculentum (Tomato lectin) (see Fig 3) are good
microglial markers in mouse astroglial cultures [24,49].
Other markers used to identify microglia in astroglial cul-
tures include the antibodies F4/80 or anti-Ionized calcium
binding adaptor molecule 1 (Iba1) and the lectins isolec-
tin-B4, Griffonia simplicifolia agglutinin (GSA) or Ricinus
Communis Agglutinin (RCA). Microglia can also be
labelled with DiI labelled acetylated-Low Density Lipo-
protein (DiI-Ac-LDL) which, unlike the microglial mark-
ers listed above, is used in living, unfixed cultures.
Microglial cells, but not astrocytes, internalize and
degrade Ac-LDL and the fluorescent probe DiI accumu-
lates in intracellular membranes [22]. The protocol is
rapid and simple. It is a good strategy to estimate the pro-
portion of microglia in sentinel wells of multiwell plates
that are subsequently used for experiments and also to fol-
low changing proportions of microglia over time. A caveat
of this method is that endothelial cells also take up Ac-
LDL [50].
When establishing the proportion of microglial cells in
astroglial cultures it is important to bear in mind that two
populations of microglial cells exist in these cultures. On
one hand, there are round refringent microglial cells,
often named amoeboid, which are located on top of the
astroglial monolayer and which can be recovered by shak-
ing. On the other hand, there are nonrefringent, ramified
Round and ramified microglia in mixed glial culturesFigure 3
Round and ramified microglia in mixed glial cultures. Bright 
field image of a murine primary cortical mixed glial culture 
stained with the microglial marker Tomato lectin (brown) 
and counterstained with hematoxylin (blue). In this field the 
proportion of microglial cells is 13%. Three of them, identi-
fied with arrows, are round microglial cells with a strong lec-
tin staining. These cells are easily identified by phase contrast 
by virtue of their refringency. In contrast, there are several 
microglial cells with ramified morphology and less intense 
lectin staining. These cells are non-refringent by phase con-
trast microscopy. Because of their weaker staining with vari-
ous microglial markers and their non-refringency, the 
proportion of ramified microglial cells in astroglial-enriched/
mixed glial cultures is often underestimated. Microglial cells 
were identified with biotin-labelled Tomato lectin (1:500, 
Sigma). Bar, 100 µm.Page 6 of 11
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monolayer or intermingled among the astrocytes and
which can be isolated by mild trypsinization [51]. For
many microglial markers the staining of refringent amoe-
boid microglial cells is stronger than that of ramified
microglial cells and this may result in an underestimation
of the proportion of ramified microglial cells (Fig 3). Sim-
ilarly, the use of phase contrast microscopy to estimate the
proportion of microglia in astroglial cultures will result in
an underestimation because refringent amoeboid micro-
glia are easily visualized with this approach but ramified
microglial cells are often indistinguishable from the sur-
rounding astrocytes [52]. An alternative approach to
microscopy for estimating microglial proportions in
astroglial-enriched cultures is flow cytometry, but this
method so far has been seldom used [53].
What is the true proportion of microglia in rodent astro-
glial-enriched cultures? This may vary from less than 1%
to 30% or even more. Several factors have an influence on
this proportion. Here I will briefly review the effects of
some parameters that may be important in this respect.
For a review on methodological aspects of astroglial cul-
tures please see [54].
Animal age
This is not a critical factor. There is no particular age that
is especially suitable to obtain astroglial cultures with low
proportions of microglia. It must considered that animal
age does affects glial activation state, and therefore can
affect cellular markers such as GFAP [55,56]. As was men-
tioned above, late embryos or newborn animals are gen-
erally preferred because they have the highest yields of
both astrocytes and microglia vs. neurons.
Species
Rat cortical astroglial cultures that are virtually devoid of
microglial cells can be obtained by subculturing at low
density [40,39,57,18,58]. The same procedure has also
been used in mouse cultures (see e.g. Additional File 1)
but in my experience this procedure is less effective at
reducing the microglial content in mouse than in rat cor-
tical astroglial cultures.
Region
There are probably no major differences in the microglial
content of astroglial cultures prepared from most CNS
regions. An exception is the substantia nigra which is par-
ticularly rich in microglial cells. As a result, the proportion
of microglial cells in mesencephalic mixed neuronal/glial
cultures is 4 to 8 times higher than that in cortical or hip-
pocampal cultures [59]. Therefore one would expect the
microglial content in mesencephalic astroglial cultures to
be also high (unless adequate strategies to minimize the
microglial content are used).
Culture medium
DMEM is the most often used medium for astroglial cul-
tures; MEM or DMEM:F12 are also common (see Addi-
tional File 1). Many variants of these basic formulations
are used to prepare astroglial cultures, e.g. with high vs.
low glucose, with or without HEPES, with or without
glutamine or Glutamax, with or without sodium bicarbo-
nate. A proper comparison on the suitability of these
media combinations for astroglial and microglial culture
has not been reported. From my experience astroglial cells
grow well both in DMEM and DMEM:F12. However,
microglial cells are less abundant in DMEM than in
DMEM:F12 astroglial cultures (unpublished observa-
tions).
Medium changes
The normal metabolism of an astroglial culture causes a
progressive reduction in nutrients in the culture medium.
In nutritionally deprived astroglial cultures astrocytes do
not survive more than a few days. In contrast, microglial
cells not only do survive well but they rapidly proliferate
[60]. Therefore, in order to keep a low microglial content
in astroglial cultures it is important to change the medium
often (every 2–3 days at least). Changing media less often,
e.g. once a week, will result in astroglial cultures with
higher microglial proportions.
Coating
Unlike neurons, astrocytes grow well on uncoated plastic
or glass surfaces but, unfortunately, so do microglia. Most
laboratories prepare their astroglial cultures on uncoated,
polylysine- or polyornithine-coated plates. Based on the
finding that laminin favors astroglial growth and inhibits
microglial growth [61] we tested the effects of laminin-
coating on astroglial cultures and found that indeed the
microglial content in astroglial cultures was markedly
reduced by laminin-coating [24]. Other groups have inde-
pendently adopted the use of laminin-coating in their
astroglial cultures [62,63]. In our laboratory, using
uncoated plastic we can obtain highly-enriched astroglial
cultures (<2% microglia) from rat, but not from mouse
cortex. To prepare astroglial-enriched cultures from
mouse cortex we routinely use laminin-coating.
Subculture
When a primary astroglial culture reaches confluence it
can be trypsinized and subcultured. This procedure results
in a secondary culture in which the proportion of micro-
glia and other contaminating cells is reduced [11]. This
simple step is very effective in rat astroglial cultures, espe-
cially if subculturing is done at relatively low densities
(<50.000 cells/cm2). As mentioned before, it has also
been used to prepare mouse astroglial cultures (see e.g.
Additional File 1), although in my experience this proce-
dure is less effective in this case.Page 7 of 11
(page number not for citation purposes)
Journal of Neuroinflammation 2007, 4:26 http://www.jneuroinflammation.com/content/4/1/26Shaking
Shaking a confluent astroglial culture in an orbital shaker
for 2 to 24 hours results in the detachment of many cells
sitting on top of the astroglial monolayer, mainly micro-
glia, type-II astrocytes and precursor cells [22]. Shaking is
therefore an effective way to reduce the proportion of
microglial cells in an astroglial culture. As noted before,
not all microglial cells are on top of the astroglial monol-
ayer. It is important to know that microglial cells located
below or in between the astroglial monolayer will not be
eliminated by shaking. Therefore, shaking can be used to
prepare highly-enriched astroglial cultures provided the
parent culture contains few microglial cells below or in
between the astrocytes.
Cytosine arabinoside (Ara-C)
Ara-C is an antimitotic drug that is used alone or in com-
bination with other strategies to reduce the presence of
microglia and other contaminating cells in astroglial cul-
tures. Ara-C must be added to cultures immediately after
astrocytes have reached confluence. At this point astro-
cytes stop proliferating because of contact inhibition and
microglia starts a phase of rapid proliferation. Most proto-
cols use Ara-C at 5–10 µM and the treatment lasts 2–5
days.
Specific microglial toxins
Another strategy to reduce the microglial content of astro-
glial cultures is the use of drugs which are toxic to micro-
glial cells and not to astrocytes. Although not used by
most laboratories, this is an effective approach to keep the
microglial content at its lowest especially when in combi-
nation with other strategies. L-leucine methyl ester, a lys-
osomotropic agent, has been often used to deplete
microglia from astroglial cultures. First used in this respect
by Giulian and Baker [22] at 5 mM for 2 hours, it has
recently been re-evaluated and strong microglial deple-
tion without astroglial "side-effects" has been obtained at
50–75 mM for 60–90 min [26]. Much less frequently used
is clodronate, a bisphosphonate known to deplete cells of
the monocyte lineage [64] that is used clinically in oste-
oporosis treatment. This drug markedly reduces the
microglial content in hippocampal organotypic cultures
[65] and could therefore be also useful in astroglial cul-
tures, but to my knowledge it has not been tested in this
respect.
Others
Strategies also exist aimed at increasing the purity of astro-
glial cultures by reducing the proportion of non-micro-
glial contaminating cells, e.g. the replacement of glucose
by sorbitol [14] which reduces the number of oli-
godendrocytes and ependymal cells, or the use of D-valine
[18] in the culture medium which retards the growth of
fibroblasts and meningeal cells. A detailed description of
these methods lies outside the scope of this review which
is focused on the presence and role of microglia in astro-
glial-enriched cultures. Finally, it is important to bear in
mind that factors such as the source of serum or the type
of plastic used in culture plates have probably an influ-
ence in the outcome of astroglial cultures and they could
also affect microglial numbers.
In summary, microglial proportions can be determined in
astroglial cultures and strategies exist that are useful at
reducing these proportions.
Conclusion
Several authors have noted previously that caution must
be used when making a claim of pure astroglial cultures
[22,26,52] and that attention must be paid to the presence
of microglia in these cultures [66,67]. Although there are
certainly groups using adequate methods to estimate and
minimize the proportion of microglia, these claims have
too often been ignored. In my opinion it is necessary that
authors, referees and editors become aware of this ques-
tion in order to reduce the number of publications in
which the presence of microglia in astroglial-enriched cul-
tures is ignored and especially those that attribute to astro-
cytes roles that are played by contaminating cells,
particularly microglia. A few suggestions to achieve this
goal are listed:
1. Microglial cells in astroglial-enriched cultures should
always be identified by specific markers, should be
counted, and the microglial proportion included in the
paper together with the proportion of astrocytes and, if
possible, with the proportions of other contaminating cell
types.
2. Those interested in working with highly-enriched astro-
glial cultures should use an adequate protocol to reduce
the proportion of microglia, e.g. laminin coating, shaking,
subculture at low density, L-leucine methyl ester, frequent
medium changes. However, the presence of microglia in
astroglial cultures is in many cases desirable because it
allows the astroglial-microglial cross talk that is extremely
important in glial activation. The point is to be aware that
microglial cells are present in these cultures and to be able
to discriminate observed effects caused by astrocytes from
those caused by microglia, from those caused by the com-
bination of the two cell types, and from those caused by
neither of them.
3. The term "pure astroglial cultures" is probably an oxy-
moron and it should be used as little as possible. I would
suggest the term "highly-enriched astroglial cultures" for
>99% astrocytes and the term "astroglial-enriched cul-
tures" for >90% (or, ideally, >95%) astrocytes. WhenPage 8 of 11
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probably more appropriate.
4. High resolution techniques (e.g. immunocytochemis-
try, in situ hybridisation) should be used to clearly
attribute an observed effect to a given cell type in astroglial
cultures. The use of both highly-enriched astroglial and
microglial cultures can also help in this respect. If these
approaches are not possible the question should be left
open and say, for example, "LPS induced an increase of X
in astroglial-enriched cultures" which is a true observation
instead of "LPS induced an increase of X in astrocytes"
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